Cell Therapy Human Raw Materials Market to Hit USD 22.75 Billion by 2034

Cell Therapy Human Raw Materials Market Size, Shares and Trends

The global cell therapy human raw materials market size was estimated at US$ 2.91 billion in 2023 and is projected to grow to US$ 22.75 billion by 2034, rising at a compound annual growth rate (CAGR) of 22.38% from 2023 to 2034. The growing demand for personalized medicine increases the demand for human raw materials required in cell therapies.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Cell Therapy Human Raw Materials Market

• By region, North America dominated the market share by 45.80% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By product, the cell culture supplements segment held the largest share of the cell therapy human raw materials market in 2023.
• By product, the cell culture media segment is anticipated to grow at the fastest rate during the forecast period.
• By end-use, the biopharmaceutical & pharmaceutical companies segment dominated the market in 2023.
• By end-use, the CROs & CMOs segment is expected to showcase the fastest CAGR during the predicted period.

Cell Therapy Human Raw Materials Market: Therapeutics

Cell therapy has become a very exciting area of study with novel therapeutic possibilities for a variety of illnesses. Although human cells are essential components for producing products for cell therapy, they frequently bring about a great deal of variability. On the other hand, the optimal collection of high-quality, consistent cellular material is made possible by strict operational controls and quality systems. The functioning of raw materials employed in cell therapy must enable desirable cellular activity. This covers the survival, differentiation, and multiplication of cells. It is crucial to choose raw materials that are suitable for the targeted therapeutic applications and the particular cell types.

How can AI Improve Cell Therapy Human Raw Materials Market?

The immense potential of artificial intelligence in healthcare is demonstrated by the industry's rapid expansion and large investments in R&D. The industrial industry is expected to face a financial effect of $3.8 trillion by 2035, while the AI market is predicted to reach an astounding $407 billion by 2027. The healthcare sector has been the most heavily invested in, with an estimated $6.1 billion in 2022. Over the past ten years, artificial intelligence (AI) and machine learning (ML) predictive techniques have transformed various biological domains, such as genome annotation, protein structure prediction, and synthetic enzyme design. By applying these predictive techniques to the creation of cell treatments, it may be possible to create better cell therapies more quickly and with fewer resources.

For instance,

• In January 2024, CellVoyant, founded by a biotechnology business with a background in artificial intelligence (AI) and spun out of the University of Bristol, secured £7.6 million in seed money to further the development of innovative cell treatments. As per the news statement dated January 16, 2024, Octopus Ventures spearheaded the investment round, which also involved participation from Horizon Ventures, Verve Ventures, and Air Street Capital.

Top Companies in the Cell Therapy Human Raw Materials Market

• Thermo Fisher Scientific, Inc
• REPROCELL
• Actylis
• STEMCELL Technologies
• ACROBiosystems
• Charles River Laboratories
• BioIVT
• PromoCell GMBH
• Pluri Inc.
• AllCells
• GeminiBio
• Akron Biotech
• Danaher
• RoosterBio, Inc.
• Grifols, S.A.
• Merck KGaA
• CGT Global

Innovation by REPROCELL in the Cell Therapy Human Raw Materials Market

Innovation by Pluri Inc. in the Cell Therapy Human Raw Materials Market

Personalized Medicine Drives the Market

The cell therapy human raw materials market is growing due to the growing demand for personalized medicines due to various genetic, autoimmune, and chronic conditions along with cancer. These diseases require personalized medicines for better quality of care and better health outcomes. During cell therapy, the genetic material of an individual is used along with environmental conditions and lifestyle to develop better cell therapies, which will require human raw materials from individuals for testing and other purposes.

Market Restraint: Risk of Contamination and Variability

One of the biggest obstacles is the inherent danger of contamination and unpredictability in human raw ingredients. Striving for repeatability in cell treatments requires maintaining consistency in cell quality and features. Therefore, possible obstacles such as contamination and variability exist.

Opportunity: Expansion of Cell Sources

Further investigation into other cell sources, such as hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs), among others, offers a chance to grow the industry. Cell treatments may be made more versatile and applicable by investigating and adding novel cell types.

There are currently close to 400 million rare illness patients globally as the frequency of these conditions rises yearly. Certain malignancies and uncommon disorders may be treated or even cured with cell and gene therapy (CGT). There may soon be a surge of novel gene treatments available. Over the next five years, it is anticipated that the CGT will almost triple. The numerous qualities of cell/gene therapy make it a wise option for treating uncommon ailments. Once mastered, replacing or repairing damaged genes is a highly reproducible strategy that may be used to treat a wide range of genetic illnesses.

For instance,

• In July 2024, the US Food and Drug Administration (FDA) established a new rare illness innovation hub with the goal of accelerating the development and approval of orphan medications. Clinical trials for rare diseases can be challenging to understand, particularly for disorders with small patient populations. Furthermore, because of the high development costs, certain rare illness medicines have been abandoned by businesses even after they have shown clinical effectiveness.

The Cell Culture Supplements Segment Dominated

By product, the cell culture supplements segment held the largest share of the cell therapy human raw materials market in 2023. With the use of cell culture supplements, labs can modify and enhance media formulations to meet the needs of certain cell culture applications, including the creation of proteins, hybridomas, Chinese hamster ovary (CHO) cells, various serum-free processes, and more. The supplements evaluated in cell culture and insect culture that are gathered here have been applied and tested to ensure that they work well in cell culture systems. Many culture parameters, including the right medium composition for your cell line, are critical to ensuring proper cell development. Basal or complex media can be improved and supplemented with lipids, vitamins, amino acids, serum, and antibiotics to assist cell development.

For instance,

• In July 2024, precision stem cell cultivation has new options thanks to the partnership between Qkine and StemCultures. The biosciences business StemCultures, which is committed to creating novel reagents that improve the quality and efficiency of cell growth and differentiation in culture, has formed a new cooperation with Qkine, a maker of specialized bioactive proteins.
• In May 2023, a performance-enhancing peptide for cell culture medium used in the production of biological medicines, cQrex® KC, will be available from Evonik. The biopharmaceutical industry's media formulators and cell culture process developers may now optimize cystine supply and boost cell culture productivity thanks to this novel peptide.

The Cell Culture Media Segment: Fastest-Growing

By product, the cell culture media segment is anticipated to grow at the fastest rate in the cell therapy human raw materials market during the forecast period. For the purpose of supplying the elements required to sustain cell growth and function, cell culture media is essential. The nutrients and growth factors your culture environment needs for the cells to behave as predicted are provided by components in the cell culture medium. Furthermore, media may be designed to control pH and osmotic pressure, two other environmental factors in cell growth. Different formulations of cell culture medium have been created to accommodate a broad range of cell types and experimental uses.

For instance,

• In July 2023, the life science division of Merck KGaA, Darmstadt, Germany, stated that MilliporeSigma, its U.S. and Canadian subsidiary, has expanded its Lenexa, Kansas, location by adding 98,000 square feet of lab space and manufacturing capacity for cell culture medium.

The Biopharmaceutical & Pharmaceutical Companies Segment Dominated

By end-use, the biopharmaceutical & pharmaceutical companies segment dominated the cell therapy human raw materials market in 2023. Cell and gene therapy is being used by pharmaceutical corporations to treat complicated medical diseases and expand treatment alternatives. Pharmaceutical corporations are strategically investing in cell and gene therapy in addition to concentrating on innovation to expand their patent portfolios. The goal of these expenditures is to put oneself at the forefront of industry innovations and close profitable partnerships with partners. A few of the most recent agreements highlight the significance of gene and cell therapy for the pharmaceutical sector.

The CROs & CMOs Segment is the Fastest Growing

By end-use, the CROs & CMOs segment is expected to showcase the fastest CAGR in the cell therapy human raw materials market during the predicted period. Biotechnology and pharmaceutical businesses frequently turn to third-party suppliers for development and manufacturing help, most frequently to CROs, CMOs, or CDMOs, in order to manage industry challenges and fill resource shortfalls. Both bio/pharma businesses and CDMOs continue to invest in the development and manufacturing capabilities for cell and gene treatments, which represent a niche but expanding industry on a product basis. Due to the industry's limited capacity for these novel modalities, CDMOs of all sizes continue to make investments in research and development as well as production capacity.

Multiple Factors Promote North America’s Dominance

By region, North America dominated the cell therapy human raw materials market share by 45.80% in 2023. The region's dominance may be attributed to supportive government policies, an increasing need for innovative treatments, and coordinated efforts by significant industry players to improve cell therapy products that treat a range of chronic illnesses. Furthermore, North America is home to a large number of well-known businesses that produce and sell cell-based goods, which is driving up demand for human raw materials for cell therapy and further expanding the market. Moreover, joint ventures between major industry participants and smaller biotechnology enterprises intensify rivalry as firms endeavor to strengthen their positions in the constantly changing cell therapy sector.

For instance,

• In May 2024, regarding the use of materials and components derived from humans and animals in the production of tissue-engineered medical products and cell and gene therapy, the FDA released a new draft of guidance for public comment. In April 2024, the FDA's Center for Biologics Evaluation and Research released the draft paper. A set of guidelines for guaranteeing the safety, identity, and quality of materials (of both human and animal origin) used in the production of tissue-engineered medical products (TEMPs) and cellular and gene therapy (CGT) products is included in the draft guidance.

Cell Therapy Demand Drives Asia Pacific’s Market

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. The rise in demand for advanced cell treatments and the heightened emphasis on biotechnology are the reasons for this surge. The market is growing because of the establishment of manufacturing facilities, strategic partnerships, and increased R&D activity by major industry players. Additionally, the Asia-Pacific region's highest market share belonged to China's Cell Therapy Human Raw Materials market, while India's Cell Therapy Human Raw Materials market grew at the quickest rate.

Recent Developments in the Cell Therapy Human Raw Materials Market

• In March 2024, the makers of cutting-edge cell and gene treatments and ex vivo cell production have the backing of ACROBiosystems, which has launched a new business effort. This effort is intended to serve as the focal point of ACROBiosystems' new purpose of "overcoming challenges from discovery to the clinic with innovation," which is a reaction to the changing global biologics manufacturing landscape. By providing progressive reagents at each level of the research-to-clinic process, ACROBiosystems hopes to streamline the process and classify its products under the lens of cell therapy modality.
• In March 2024, NHS Blood and Transplant (NHSBT) is establishing a state-of-the-art facility that will significantly enhance the UK's capacity to research, develop, and produce novel gene and cell treatments. It will produce goods for the creation of possibly healing treatments for illnesses, including sickle cell disease, cystic fibrosis, and some types of cancer that are now incurable. A portion of these will be individualized treatments meant to treat a single patient.

Segments Covered in the Report

By Product

• Cell Culture Supplements
  • Proteins
  • Growth Factors
  • Nucleotides
  • Other Supplements
• Cell Culture Media
• Cell Culture Sera
• Reagents & Buffers
• Other Raw Materials

By End-Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailands
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait